secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2026-05-15T20:08:07+00:00
Accession:  0001651308-26-000012
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeOne Medicines gets FDA accelerated approval for BEQALZI (sonrotoclax) in R/R MCL
--------------------------------------------------------------------------------

- FDA approved BEQALZI for R/R mantle cell lymphoma after ≥2 prior therapies including a BTK inhibitor.
- Phase 1/2 trial showed ORR 52%, CR 16%, median DOR 15.8 months; safety generally well tolerated.
- Continued approval contingent on confirmatory CELESTIAL-RRMCL trial (NCT06742996) now underway.
- BEQALZI is the first new BCL2 inhibitor approved in the U.S. in a decade and the only one for MCL.
- Also approved in China for R/R MCL and CLL/SLL; EMA review ongoing; Fast Track for Waldenström.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130826000012/0001651308-26-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130826000012/bgne-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001651308-26-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer